TianYu Bio-Technology Co (SHSE:603717) EBIT: ¥-76.4 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603717 TianYu Bio-Technology Co Ltd SHSE:603717
54 GF Score
Price ¥6.01
GF Value ¥5.72
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is TianYu Bio-Technology Co EBIT?

TianYu Bio-Technology Co SHSE:603717 -0.99% 54 EBIT is ¥-76.4 Mil as of Mar. 2026. GuruFocus rates SHSE:603717 with a GF Score™ of 54/100 and a GF Value™ of ¥5.72 (Fairly Valued). The stock has 5 warning signs investors should review.

TianYu Bio-Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥5.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-76.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TianYu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 was -1.40%. TianYu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TianYu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.69%.


TianYu Bio-Technology Co  (SHSE:603717) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TianYu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-32.396 * ( 1 - 2.89% )/( (2250.477 + 2235.423)/ 2 )
=-31.4597556/2242.95
=-1.40 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2893.139 - 841.812 - ( 161.826 - max(0, 1325.629 - 1126.479+161.826))
=2250.477

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2869.224 - 771.894 - ( 132.937 - max(0, 1213.711 - 1075.618+132.937))
=2235.423

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TianYu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=23.4/( ( (485.265 + max(-304.987, 0)) + (507.533 + max(-246.788, 0)) )/ 2 )
=23.4/( ( 485.265 + 507.533 )/ 2 )
=23.4/496.399
=4.71 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(299.202 + 224.712 + 212.43) - (841.812 + 0 + 199.519)
=-304.987

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(256.049 + 240.31 + 226.153) - (771.894 + 0 + 197.406)
=-246.788

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TianYu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-76.445/2847.106
=-2.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TianYu Bio-Technology Co EBIT Related Terms


TianYu Bio-Technology Co EBIT Historical Data

* Premium members only.

The historical data trend for TianYu Bio-Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TianYu Bio-Technology Co EBIT Chart

TianYu Bio-Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -186.94 -287.61 -548.03 -50.63 -42.89

TianYu Bio-Technology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.40 20.53 -2.45 -100.38 5.85

SHSE:603717 vs PWR, FIX, EME: EBIT Comparison

For the Engineering & Construction subindustry, TianYu Bio-Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TianYu Bio-Technology Co EV-to-EBIT vs Construction Industry

For the Construction industry and Industrials sector, TianYu Bio-Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TianYu Bio-Technology Co's EV-to-EBIT falls into.


SHSE:603717
54GF Score
TianYu Bio-Technology Co Ltd SHSE:603717
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TianYu Bio-Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-76.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥-76.4 Mil mean?
TianYu Bio-Technology Co (SHSE:603717) has a EBIT of ¥-76.4 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TianYu Bio-Technology Co.
Is TianYu Bio-Technology Co's EBIT too high?
TianYu Bio-Technology Co's current EBIT is ¥-76.4 Mil. Overall, TianYu Bio-Technology Co has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TianYu Bio-Technology Co's EBIT compare to PWR and FIX?
TianYu Bio-Technology Co's EBIT of ¥-76.4 Mil can be compared against companies in the Construction industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Construction company?
A good EBIT depends on the Construction industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TianYu Bio-Technology Co. TianYu Bio-Technology Co's current EBIT is ¥-76.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TianYu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, TianYu Bio-Technology Co (SHSE:603717) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.72, compared to a current price of ¥6.01 — trading 5.1% above its estimated fair value. The current EBIT is ¥-76.4 Mil. TianYu Bio-Technology Co's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TianYu Bio-Technology Co (SHSE:603717), the current EBIT is ¥-76.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TianYu Bio-Technology Co (SHSE:603717) Overvalued in 2026?

Based on GuruFocus' analysis, TianYu Bio-Technology Co stock appears to be overvalued. The current stock price of ¥6.01 is trading 5.1% above its estimated GF Value™ of ¥5.72. GuruFocus considers TianYu Bio-Technology Co to be Fairly Valued.

Key valuation signals for SHSE:603717:

  • EBIT: ¥-76.4 Mil
  • GF Value™: ¥5.72 vs. price of ¥6.01 (5.1% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TianYu Bio-Technology Co Business Description

Address Lane 1688, Guoquan North Road, 2nd Floor, Building C4, Wangu Technology Park, Yangpu District, Shanghai, CHN, 200433
TianYu Bio-Technology Co Ltd is engaged in Garden ecological engineering business, ecological environment management and rural complex business, pig breeding business, production and marketing of agricultural products and cash crops.
54GF Score

Get the complete analysis for SHSE:603717

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.01
Price
¥5.72
GF Value